Browse the search results

A genetic discovery screen for epigenetic factors accelerating melanoma development in vivo identifies SATB2 as a driver of tumor invasion and resistance to FDA-approved BRAF-targeted inhibitor Vemurafenib.

Transformation mediated by oncogenic BRAF requires transcriptional activation of TWIST at the earliest stage of neoplastic transformation.

Two of the most commonly mutated growth factor pathways induce a deadly feature of lung adenocarcinoma.

3D culture of breast cancer in biologically relevant ECM potentiates the growth-inhibitory effects of unacylated ghrelin and AZP-531, and clinical response may be predictable based on a MAPK gene signature.

RNF43 interacts with receptor complexes of the Wnt/PCP signaling and its enzymatic activity results in the reduced cells sensitivity to WNT5A what translates in melanoma into decreased invasive properties and increased response to targeted therapies of this skin cancer.

Pre-clinical and patient data show that inhibition of autophagy with an approved, inexpensive, well-tolerated drug can overcome resistance to BRAF^V600E inhibition in multiple brain tumor subtypes with different resistance mechanisms.

Live imaging of the duel of an NK cell versus a metastatic cancer cell on pulmonary epithelial cells reveals a novel survival tactics adopted by cancer cells.

Gene copy number provides more prognostic information than gene mutation status in cancer.